Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Ascendis Pharma‘s TransCon PTH can safely treat hypoparathyroidism, reducing the need for other therapies and improving patients’ quality of life, an extension period of the PaTH Forward Phase 2 ... Read more
TransCon PTH, an investigational therapy being developed by Ascendis Pharma, safely normalized calcium and phosphate levels, and reduced the need for other treatments in adults with hypoparathyroidism, data from ... Read more
ProLynx has been awarded a small business innovation research grant from the National Institutes of Health (NIH) to develop its long-acting parathyroid hormone (PTH) therapy — known as PTH(1-34) — ... Read more
Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism treatment known as AZP-3601 later this year. “Our new name, Amolyt Pharma, ... Read more
Lower levels of parathyroid hormone (PTH) in people with hypoparathyroidism may lead to decreased bone material strength and increase the risk of fractures, a new study reports. The study, ... Read more
A Phase 2 trial testing the experimental therapy TransCon PTH in adults with hypoparathyroidism is expanding to allow for faster enrollment of people previously treated with Natpara (parathyroid hormone, ... Read more
Pin It on Pinterest